Market Closed - London S.E. 11:35:01 2024-04-18 am EDT 5-day change 1st Jan Change
5.875 GBX +2.17% Intraday chart for genedrive plc -4.08% -27.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FTSE 100 up thanks to US economic data AN
Genedrive shares surge as UK's NICE backs test for ischaemic stroke AN
AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal AN
Genedrive's Test Receives Draft Recommendation from UK's NICE MT
EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate AN
Genedrive plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Genedrive down as plans equity raise despite GBP800,000 tax credit AN
Coro seals sale terms, Powerhouse makes good progress AN
Genedrive Seeks Funding for Testing Kit Amid Funding Call Launch of UK-backed Program MT
MoneySupermarket credits Insurance for growth in 2023 AN
Genedrive draws down GBP600,000 on prepayment facility AN
Genedrive Secures Financing Under Equity Prepayment Facility MT
AIM WINNERS & LOSERS: Genedrive shares jump on orders AN
Genedrive shares surge as six countries receive first orders AN
Genedrive Jumps on Receipt of Initial Orders for MT-RNR1 Products MT
Genedrive plc Announces Initial Overseas Orders of Mt-RNR1 Id Kit CI
600 Group disposal and funding talks continue AN
Genedrive plc Announces the Genedrive MT-RNR1 Id Kit Is Now in Routine Use in the Trevor Mann Baby Unit CI
Genedrive shares fall as annual loss widens but focused on investing AN
Earnings Flash (GDR.L) GENEDRIVE Reports FY23 Revenue GBP55,000 MT
Earnings Flash (GDR.L) GENEDRIVE Posts FY23 Loss GBX-5.50 MT
Genedrive plc Reports Earnings Results for the Full Year Ended June 30, 2023 CI
EARNINGS AND TRADING: Southern Energy loss swing; Craven House widens AN
Genedrive to receive GBP1.2 million grant for test kit AN
Genedrive Shares Rise on GBP1.2 Million Grant to Validate Test Kit DJ
Chart genedrive plc
More charts
genedrive plc is a United Kingdom-based patient molecular diagnostics company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company offers products, including Genedrive MT-RNR1 ID Kit and Genedrive COV19-ID Kit. Genedrive MT-RNR1 ID Kit is a rapid genetic test in an emergency neonatal care setting. It has developed tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of hepatitis c virus (HCV), infection prior to drug administration, pathogen detection of biological military threats, and a point-of-care for COVID-19 detection system for us in areas such as healthcare, workplace screening, travel requirements, or confirmation of antigen tests.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock Market
  2. Equities
  3. GDR Stock
  4. News genedrive plc
  5. Genedrive : Rises 7% as Study Shows 100% Accuracy of Hepatitis C Virus Testing Kit in India